GlassScriptPhysician profile
Dan H Frissell
NPI 1407829849
$2,750.68
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $310 · 2021: $367 · 2022: $721 · 2023: $641 · 2024: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.41 | 2019-2024 | |
| Janssen Biotech, INC. | $342.76 | 2019-2023 | Tremfya |
| Lilly USA, LLC | $270.94 | 2019-2024 | Mounjaro, Trulicity, Taltz |
| Amgen INC. | $225.83 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $158.39 | 2019-2024 | |
| Novo Nordisk INC | $89.37 | 2019-2024 | Rybelsus, Ozempic |
| Mallinckrodt Hospital Products INC. | $88.26 | 2022-2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $86.78 | 2022-2023 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $74.40 | 2022-2024 | |
| Grifols USA, LLC | $63.26 | 2019-2023 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $54.53 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $49.42 | 2019 | |
| Allergan, INC. | $48.28 | 2019-2020 | |
| Radius Health, INC. | $48.24 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.59 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.80 | 2019-2024 | Trelegy Ellipta |
| Mallinckrodt Enterprises LLC | $41.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.08 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $36.26 | 2022-2023 | Strensiq |
| Takeda Pharmaceuticals U.S.A., INC. | $33.89 | 2019-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $31.15 | 2019 | |
| Amarin Pharma, INC. | $24.16 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.38 | 2021 | |
| Organon LLC | $21.81 | 2023 | Renflexis, Hadlima |
| Abbott Laboratories | $21.02 | 2022 | |
| Apria Healthcare LLC | $20.61 | 2021 | |
| Eisai INC. | $17.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.33 | 2020 | |
| Merck Sharp & Dohme LLC | $15.87 | 2024 | Verquvo |
| Ani Pharmaceuticals, INC. | $14.96 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Frissell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.